Related Experiment Video
Updated: Jun 30, 2025
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions
Mark H Rozenbaum1, Erica Chilson2, Raymond Farkouh2
1Value and Evidence Team, Pneumococcal Vaccines, Pfizer Inc., Capelle a/d Ijssel, The Netherlands. mark.rozenbaum@pfizer.com.
Insights
The 20-valent pneumococcal conjugate vaccine (PCV20) is a cost-effective strategy for children with chronic medical conditions (CMC+) and immunocompromising conditions (IC). PCV20 reduces pneumococcal disease cases and healthcare costs, offering significant savings from both societal and healthcare perspectives.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Health Economics
Background:
- A 20-valent pneumococcal conjugate vaccine (PCV20) is now recommended for children in the US.
- Pneumococcal disease poses risks to children with chronic medical conditions (CMC+) and immunocompromising conditions (IC).
Purpose of the Study:
- To evaluate the cost-effectiveness of PCV20 compared to pneumococcal polysaccharide vaccine (PPSV23) in children aged 6 years with CMC+ and IC.
- To assess the impact of PCV20 on pneumococcal disease incidence, clinical outcomes, and economic costs.
Main Methods:
- A 10-year probabilistic model was used to simulate the risk of pneumococcal disease outcomes and associated costs.
- Vaccine uptake was assumed at 20% for both PCV20 and PPSV23.
- Cost per quality-adjusted life year (QALY) gained was calculated from US societal and healthcare system perspectives, with sensitivity analyses conducted.
Main Results:
- PCV20 is projected to reduce pneumococcal disease cases by over 5200 and save millions in medical and nonmedical costs for children with CMC+.
- PCV20 was the dominant strategy over PPSV23 in both healthcare and societal perspectives, with 99.9% of simulations supporting this finding.
- Comparable results were observed for children with IC, and increasing PCV20 uptake to 100% could prevent over 22,000 additional cases and save $70 million.
Conclusions:
- PCV20 use in US children with CMC+ and IC significantly reduces the clinical burden of pneumococcal disease.
- PCV20 vaccination yields overall cost savings for both the US healthcare system and society.
- Higher PCV20 uptake can further decrease pneumococcal disease incidence in this vulnerable pediatric population.
Introduction:
A 20-valent pneumococcal conjugate vaccine (PCV20) was recently recommended for use among US children. We evaluated the cost-effectiveness of PCV20 among children aged 6 years with chronic medical conditions (CMC+) and children aged 6 years with immunocompromising conditions (IC) versus one and two doses of 23-valent pneumococcal polysaccharide vaccine (PPSV23), respectively.
Methods:
A probabilistic model was employed to depict 10-year risk of clinical outcomes and economic costs of pneumococcal disease, reduction in life years from premature death, and expected impact of vaccination among one cohort of children with CMC+ and IC aged 6 years. Vaccine uptake was assumed to be 20% for both PCV20 and PPSV23. Cost per quality-adjusted life year (QALY) gained was evaluated from the US societal and healthcare system perspectives; deterministic and probabilistic sensitivity analyses (DSA/PSA) were also conducted.
Results:
Among the 226,817 children with CMC+ aged 6 years in the US, use of PCV20 (in lieu of PPSV23) was projected to reduce the number cases of pneumococcal disease by 5203 cases, medical costs by US$8.7 million, and nonmedical costs by US$6.2 million. PCV20 was the dominant strategy versus PPSV23 from both the healthcare and societal perspectives. In the PSA, 99.9% of the 1000 simulations yielded a finding of dominance for PCV20. Findings in analyses of children with IC aged 6 years in the USA were comparable (i.e., PCV20 was the dominant vaccination strategy). Scenario analyses showed that increasing PCV20 uptake to 100% could potentially prevent > 22,000 additional cases of pneumococcal disease and further reduce medical and nonmedical costs by US$70.0 million among children with CMC+ and IC.
Conclusions:
Use of PCV20 among young children with CMC+ and IC in the USA would reduce the clinical burden of pneumococcal disease and yield overall cost savings from both the US healthcare system and societal perspectives. Higher PCV20 uptake could further reduce the number of pneumococcal disease cases in this population.
More Related Videos
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:51Vaccinations
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:25Immunodeficiency Diseases
There are three main causes of immunodeficiency...